论文部分内容阅读
Wide availability of systemic therapy agents has led to a considerable decline in the mortality from breast cancer.However, the biology of breast cancer remains poorly understood.Currently, highly accurate markers to predict prognosis and probability of response to a given systemic therapy on an individual bases are lacking, and routinelyused clinicopathologic variables fail to fully capture the heterogeneity of breast cancer.As a result, many patients are overtreated whereas others may not receive the necessary therapy.